Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice

Cardiovascular Research

Volumn 97, Issue 3, 2013, Pages 580-588

  Wan, Wuzhou ^a   Lionakis, Michail S ^a   Liu, Qian ^a   Roffê, Ester ^a   Murphy, Philip M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Aorta; Atherosclerosis; Inflammation; Leucocytes

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CCR7; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIPID ANALYSIS; LIPID DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; INTERLEUKIN-12; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, CCR7; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84874268379     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs349     Document Type: Article

References (33)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
2. Packard RR, Lichtman AH, Libby P. Innate and adaptive immunity in atherosclerosis. Semin Immunopathol 2009;31:5-22.
3. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011;17:1410-1422.
4. Koenen RR, Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med 2011;3:713-725.
5. Wan W, Lim JK, Lionakis MS, Rivollier A, McDermott DH, Kelsall BL et al. Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice. Circ Res 2011;109:374-381.
6. Fö rster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008;8:362-371.
7. Beauvillain C, Cunin P, Doni A, Scotet M, Jaillon S, Loiry ML et al. CCR7 is involved in the migration of neutrophils to lymph nodes. Blood 2011;117:1196-1204.
8. Damas JK, Smith C, Øie E, Fevang B, Halvorsen B, Waehre T et al. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol 2007;27:614-620.
9. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006;103:3781-3786.
10. Luchtefeld M, Grothusen C, Gagalick A, Jagavelu K, Schuett H, Tietge UJ et al. Chemokine receptor 7 knockout attenuates atherosclerotic plaque development. Circulation 2010;122:1621-1628.
11. Potteaux S, Gautier EL, Hutchison SB, van Rooijen N, Rader DJ, Thomas MJ et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/-mice during disease regression. J Clin Invest 2011;121:2025-2036.
12. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009;27:165-197.
13. Feig JE, Shang Y, Rotllan N, Vengrenyuk Y, Wu C, Shamir R et al. Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One 2011;6:e28534.
14. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99:23-33.
15. Sallusto F, Lenig D, Fö rster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-712.
16. Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB et al. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol 2005;6:889-894.
17. Bromley SK, Thomas SY, Luster AD. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat Immunol 2005;6:895-901.
18. Moschovakis GL, Bubke A, Dittrich-Breiholz O, Braun A, Prinz I, Kremmer E et al. Deficient CCR7 signaling promotes TH2 polarization and B-cell activation in vivo. Eur J Immunol 2012;42:48-57.
19. Nickel T, Pfeiler S, Summo C, Kopp R, Meimarakis G, Sicic Z et al. oxLDL downregulates the dendritic cell homing factors CCR7 and CCL21. Mediators Inflamm 2012;2012:320953.
20. Braunersreuther V, Zernecke A, Steffens S, Shagdarsuren E, Bidzhekov K, Burger F et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007;27:373-379.
21. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008;102:209-217.
22. Potteaux S, Combadiere C, Esposito B, Casanova S, Merval R, Ardouin P et al. Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice. Mol Med 2005;11:16-20.
23. Wendland M, Willenzon S, Kocks J, Davalos-Misslitz AC, Hammerschmidt SI, Schumann K et al. Lymph node T cell homeostasis relies on steady state homing of dendritic cells. Immunity 2011;35:945-957.
24. Schneider MA, Meingassner JG, Lipp M, Moore HD, Rot A. CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 2007;204:735-745.
25. Moschovakis GL, Fö rster R. Multifaceted activities of CCR7 regulate T-cell homeostasis in health and disease. Eur J Immunol 2012;42:1949-1955.
26. Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999;19:734-742.
27. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003;163:1117-1125.
28. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:969-979.
29. Butcher M, Galkina E. Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost 2011;106:787-795.
30. Hall BM, Verma ND, Tran GT, Hodgkinson SJ. Distinct regulatory CD4+T cell subsets: differences between na?̈ve and antigen specific T regulatory cells. Curr Opin Immunol 2011;23:641-647.
31. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamaté C, Merval R et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001;89:930-934.
32. Gojova A, Brun V, Esposito B, Cottrez F, Gourdy P, Ardouin P et al. Specific abrogation of transforming growth factor-b signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 2003;102:4052-4058.
33. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-b signaling in T cells accelerates atherosclerosis. J Clin Invest 2003;112: 1342-1350.